Yamada M, Omata K, Abe F, Ito S, Abe K
The Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Immunopharmacology. 1999 Oct 15;44(1-2):193-8. doi: 10.1016/s0162-3109(99)00137-x.
Prostacyclin (PGI2), thromboxane A2 (TXA2) and F2-isoprostanes, prostaglandin F2-like compounds, have wide and contrasting spectrum of biological activities and may influence blood pressure and atherogenesis. To investigate the dynamics of PGI2, TXA2 and F2-isoprostanes in patients with hypertension and hyperlipidemia (HH group), we measured the major urinary metabolites of PGI2: 6-keto PGF1alpha (Keto) and 2,3-dinor-6-keto PGF1alpha, (Dinor), those of TXA2:TXB2 and 11-dehydro TXB2 (Dehydro), and urinary 8-isoprostane (Iso) in 34 patients. Urinary excretion of Dinor was significantly lower in patients than in controls and that of Dehydro was significantly higher in patients than in controls. Keto, TXB2 and Iso were not significantly different between them. Antiplatelet agents decreased not only TXA2 metabolites but also PGI2 metabolites. Urinary C-peptide immunoreactivity was correlated with Dinor and Dehydro. After administration of eicosapentaenoic acid (EPA), total cholesterol (T-cho) and triglycerides (TG) significantly decreased. Although prostanoids did not show significant change, changes in T-cho were correlated with changes in Dinor and changes in Iso. These results suggest that PGI2 and TXA2 of systemic origin might be related to the pathophysiology of hypertension and hyperlipidemia and that the dynamics of PGI2, TXA2 and F2-isoprostanes might be related to not only blood pressure regulation but also lipid and glucose metabolism.
前列环素（PGI2）、血栓素A2（TXA2）和F2-异前列腺素（前列腺素F2样化合物）具有广泛且截然不同的生物活性谱，可能影响血压和动脉粥样硬化的发生。为了研究高血压和高脂血症患者（HH组）中PGI2、TXA2和F2-异前列腺素的动态变化，我们测量了34例患者中PGI2的主要尿代谢产物：6-酮基PGF1α（酮基）和2,3-二去甲-6-酮基PGF1α（去甲）、TXA2的代谢产物：TXB2和11-脱氢TXB2（脱氢）以及尿8-异前列腺素（异前列腺素）。患者的去甲尿排泄量显著低于对照组，而脱氢的排泄量显著高于对照组。酮基、TXB2和异前列腺素在两者之间无显著差异。抗血小板药物不仅降低了TXA2代谢产物，也降低了PGI2代谢产物。尿C肽免疫反应性与去甲和脱氢相关。给予二十碳五烯酸（EPA）后，总胆固醇（T-cho）和甘油三酯（TG）显著降低。尽管类前列腺素没有显示出显著变化，但T-cho的变化与去甲的变化以及异前列腺素的变化相关。这些结果表明，全身来源的PGI2和TXA2可能与高血压和高脂血症的病理生理学有关，并且PGI2、TXA2和F2-异前列腺素的动态变化可能不仅与血压调节有关，还与脂质和葡萄糖代谢有关。
